Imeglimin Alleviates High-Glucose-Induced Bioenergetic and Oxidative Stress Thereby Enhancing Intercellular Adhesion in H9c2 Cardiomyoblasts
Open Access
- 12 September 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8913
Abstract
To elucidate the effects of the new antidiabetic agent, imeglimin (Ime, 2 mM), on high-glucose-induced cellular stress in cardiac cells, its effects were compared with those of the conventional antidiabetic agent metformin (Met, 2 mM) based on various cellular pathophysiological functions. H9c2 cardiomyoblasts were cultured under normal-glucose (5.5 mM, N-Glu) or high-glucose (50 mM, H-Glu) conditions. Cellular metabolic function was evaluated using a Seahorse XFe96 Bioanalyzer, along with measurements of reactive oxygen species (ROS) production, expression levels of the autophagy-related marker LC3, and intercellular adhesion properties measured based on transepithelial electrical resistance (TEER). Cells cultured under H-Glu conditions showed enhanced mitochondrial and glycolytic activities, which were suppressed by Met or Ime. Under H-Glu conditions, total cellular ROS (t-ROS) levels were significantly increased. Met had little effect on t-ROS under H-Glu conditions, whereas Ime markedly reduced both t-ROS and mitochondrial ROS (m-ROS) levels under H-Glu conditions. The LC3-II/LC3-I ratio, a marker of autophagic activity, decreased under H-Glu conditions; however, this reduction was not significantly affected by treatment with either Met or Ime. Regarding intercellular adhesion properties, TEER values were elevated under H-Glu conditions compared to N-Glu conditions, and those under H-Glu conditions were further increased by Ime but not Met. In support of these results, the mRNA levels of cell-adhesion-related molecules, including β-catenin and N-cadherin, were also altered by Ime. Collectively, Ime modulated high-glucose-induced alterations in the biological properties of H9c2 cardiomyoblasts, independent of changes in autophagic activity.Keywords
Funding Information
- the educational research grant of Sapporo Medical University (T.S. 22K08210, 25K11392)
- Japan Society for the Promotion of Science (T.S. 22K08210, 25K11392)
This publication has 66 references indexed in Scilit:
- The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cellsEndocrinology, Diabetes & Metabolism, 2021
- Imeglimin: Current Development and Future Potential in Type 2 DiabetesDrugs, 2020
- High-glucose-induced apoptosis, ROS production and pro-inflammatory response in cardiomyocytes is attenuated by metformin treatment via PP2A activationJournal of Biosciences, 2020
- Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitusEuropean Journal of Clinical Pharmacology, 2020
- Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndromeEndocrinology, Diabetes & Metabolism, 2020
- A review of phenformin, metformin, and imegliminDrug Development Research, 2020
- Toxic effect of high glucose on cardiomyocytes, H9c2 cells: Induction of oxidative stress and ameliorative effect of troloxJournal of Biochemical and Molecular Toxicology, 2018
- Therapeutic Concentrations of Metformin: A Systematic ReviewClinical Pharmacokinetics, 2015
- HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cellsCellular and Molecular Life Sciences, 2011
- Diabetic cardiomyopathy, causes and effectsReviews in Endocrine and Metabolic Disorders, 2010